NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 ...

Shelton, Connecticut Thursday, July 17, 2025, 18:00 Hrs [IST] ...

Moleculin Biotech (MBRX) announced that the Regulation Agency for Medical and Pharmaceutical Activities, or RAMPA, in the country of Georgia has ...

A new study by investigators from Europe, including the Netherlands and the United Kingdom (UK), has shed light on significant ethical, administrative, regulatory, and logistical (EARL) hurdles in ...

BACKGROUND: Neurodevelopmental and functional impairments are among the most consequential morbidities for survivors of ...

ARPA-H, part of HHS, has earmarked up to $142 million for 10 research projects building the tools, data, and infrastructure needed to tackle treatment resistance.

Artificial Intelligence (AI) is no longer just a buzzword it is transforming the way healthcare is delivered and its influence is now reaching deep into the world of clinical trials from predicting ...

Artificial intelligence (AI) should soon be taking a greater role in areas including patient recruitment and in building efficiencies around data quality.

How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical ...

Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 MIRACLE trial Recent EU approval from the European Medicines Agency (EMA) boosts ...